# EDGAR Filing Document

**Accession Number:** 0001722926
**File Stem:** 0000000000-23-003231
**Filing Date:** 2023-3
**Character Count:** 3364
**Document Hash:** 3c838690e2c720ae488d52ed38415fe4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-003231.hdr.sgml**: 20230504

**ACCESSION NUMBER**: 0000000000-23-003231

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230330

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASLAN Pharmaceuticals Ltd
- **CENTRAL INDEX KEY:** 0001722926
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 83 CLEMENCEAU AVENUE
- **STREET 2:** #12-03 UE SQUARE
- **CITY:** SINGAPORE
- **STATE:** U0
- **ZIP:** 239920
- **BUSINESS PHONE:** 65 6222 4235

**MAIL ADDRESS:**
- **STREET 1:** 83 CLEMENCEAU AVENUE
- **STREET 2:** #12-03 UE SQUARE
- **CITY:** SINGAPORE
- **STATE:** U0
- **ZIP:** 239920
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-23-079208

## Text-Extract

```

United States securities and exchange commission logo

                          March 30, 2023

       Carl Firth, Ph.D.
       Chief Executive Officer
       ASLAN Pharmaceuticals Limited
       3 Temasek Avenue
       Level 18 Centennial Tower
       Singapore 039190

                                                        Re: ASLAN
Pharmaceuticals Limited
                                                            Registration
Statement on Form F-3
                                                            Filed March 24,
2023
                                                            File No. 333-270837

       Dear Carl Firth:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Alan
Campbell at 202-551-4224 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Carlos Ramirez

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 30, 2023

Carl Firth, Ph.D.
Chief Executive Officer
ASLAN Pharmaceuticals Limited
3 Temasek Avenue
Level 18 Centennial Tower
Singapore 039190

Re: ASLAN Pharmaceuticals Limited
Registration Statement on Form F-3
Filed March 24, 2023
File No. 333-270837

Dear Carl Firth:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Carlos Ramirez